XNAS · Healthcare · Biotechnology
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | — | 0.00 | — | $0 | — | +3.53% | +2.53% | — |
| 2026-03-19 | Q4 2025 | — | 0.00 | — | $0 | — | -11.11% | -13.45% | +31.58% |
| 2025-11-13 | Q3 2025 |
| — |
| 0.00 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-08-20 | Q2 2025 | — | 0.00 | — | $0 | — | +0.32% | +4.18% | +18.65% |
| 2025-03-20 | Q4 2024 | -0.09 | -0.32 | -255.56% | $0 | ❌ Miss | -2.16% | +32.59% | -2.11% |
| 2024-11-25 | Q3 2024 | -4.29 | -2.28 | +46.85% | $0 | ✅ Beat | +5.56% | +0.00% | +5.56% |
| 2024-08-15 | Q2 2024 | -2.35 | -0.15 | +93.62% | $0 | ✅ Beat | +6.38% | +144.38% | +93.62% |
| 2024-05-16 | Q1 2024 | -3.49 | -3.25 | +6.88% | $0 | ✅ Beat | -2.72% | -4.09% | -18.53% |
Showing last 8 quarters.